Novartis AG (NYSE:NVS) has been assigned a $90.00 price target by Cowen and Company in a note issued to investors on Wednesday. The brokerage currently has a “hold” rating on the stock. Cowen and Company’s target price indicates a potential upside of 6.91% from the company’s previous close.

Other research analysts have also recently issued reports about the company. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Novartis AG in a report on Thursday, June 22nd. UBS AG reaffirmed a “neutral” rating on shares of Novartis AG in a report on Tuesday, May 30th. Leerink Swann reaffirmed a “market perform” rating and issued a $83.00 price target on shares of Novartis AG in a report on Thursday, June 22nd. Vetr cut Novartis AG from a “buy” rating to a “hold” rating and set a $78.32 price target for the company. in a report on Tuesday, April 25th. Finally, Barclays PLC raised Novartis AG from an “underweight” rating to an “equal weight” rating in a report on Thursday, June 22nd. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $83.56.

Novartis AG (NYSE NVS) opened at 84.18 on Wednesday. Novartis AG has a 12 month low of $66.93 and a 12 month high of $86.90. The company has a market cap of $197.22 billion, a price-to-earnings ratio of 30.73 and a beta of 0.73. The company has a 50-day moving average of $84.23 and a 200-day moving average of $78.55.

Novartis AG (NYSE:NVS) last released its quarterly earnings results on Tuesday, July 18th. The company reported $1.22 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.16 by $0.06. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The business had revenue of $12.24 billion during the quarter, compared to analysts’ expectations of $12.20 billion. During the same period in the previous year, the business posted $1.23 earnings per share. The firm’s revenue for the quarter was down 1.8% compared to the same quarter last year. Analysts predict that Novartis AG will post $4.73 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Novartis AG (NYSE:NVS) PT Set at $90.00 by Cowen and Company” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.watchlistnews.com/novartis-ag-nysenvs-pt-set-at-90-00-by-cowen-and-company/1467642.html.

In related news, major shareholder Bioventures Ltd Novartis bought 266,667 shares of the firm’s stock in a transaction dated Wednesday, July 5th. The stock was bought at an average cost of $15.00 per share, for a total transaction of $4,000,005.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.01% of the company’s stock.

Several institutional investors have recently bought and sold shares of NVS. Westwood Holdings Group Inc. raised its position in Novartis AG by 5.6% in the first quarter. Westwood Holdings Group Inc. now owns 5,405 shares of the company’s stock valued at $401,000 after buying an additional 285 shares during the last quarter. AT Bancorp raised its position in Novartis AG by 4.2% in the first quarter. AT Bancorp now owns 11,690 shares of the company’s stock valued at $868,000 after buying an additional 470 shares during the last quarter. Physicians Financial Services Inc. raised its position in Novartis AG by 11.4% in the first quarter. Physicians Financial Services Inc. now owns 16,583 shares of the company’s stock valued at $1,232,000 after buying an additional 1,700 shares during the last quarter. Prentiss Smith & Co. Inc. raised its position in Novartis AG by 2.4% in the first quarter. Prentiss Smith & Co. Inc. now owns 136,441 shares of the company’s stock valued at $10,133,000 after buying an additional 3,239 shares during the last quarter. Finally, Mawer Investment Management Ltd. raised its position in Novartis AG by 2.9% in the first quarter. Mawer Investment Management Ltd. now owns 3,122,065 shares of the company’s stock valued at $231,876,000 after buying an additional 88,610 shares during the last quarter. Institutional investors own 11.27% of the company’s stock.

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Analyst Recommendations for Novartis AG (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.